PYC Therapeutics Ltd
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases.
The business
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Small Caps Research
No research on PYC Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PYC based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
PYC Therapeutics advances groundbreaking treatment for Phelan-McDermid syndrome
PYC Therapeutics (ASX: PYC) has made a breakthrough with its main drug candidate for the potential treatment of neurodevelopmental disorder Phelan-McDermid Syndrome (PMS). New studies by PYC have found it can restore the deficient protein that causes PMS in neurons, the brain cells in which the disorder occurs. The neurons in which these results have […]
Phylogica achieves milestone in drug study aimed at treating childhood blindness
Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. The company today reported results from its flagship drug program, in which its proprietary drug delivery technology was used on a 3D model […]
Phylogica’s cell penetrating platform linked to effective administration of drugs for genetic eye disease
A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patients with genetic eye disease. A competitive evaluation test on animal models using Phylogica’s proprietary cell penetrating platform demonstrated the technology could significantly increase the effectiveness of an […]
Phylogica’s cell peptide delivery platform achieves early success in human cell studies for blinding eye diseases
Perth-based biotech company Phylogica (ASX: PYC) has reported positive early stage results from a pilot study of human cells using its proprietary drug delivery technology to create a treatment for blinding genetic eye diseases. The study delivered an anti-sense oligonucleotide (ASO) drug cargo into human retinal pigment epithelial cells using Phylogica’s cell penetrating peptide (CPP) […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.